Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

ImmunityBio

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2014-01-01

Employees: 628

Market Cap: $2.9B

Website: http://www.immunitybio.com

Introduction: ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Clinical Trials

Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

Phase 3

Completed

Conditions: Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma

Interventions: Drug: Aldoxorubicin
Drug: Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)

First Posted Date: 2014-01-30

Last Posted Date: 2024-06-13

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 433

Registration Number: NCT02049905

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Arizona Oncology Associates, PC, Phoenix, Arizona, United States
🇺🇸
The University of Arizona, Tucson, Arizona, United States

and more 70 locations

A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma

Phase 2

Completed

Conditions: HIV Positive
Kaposi's Sarcoma
AIDS

Interventions: Drug: 150 mg/m2 aldoxorubicin
Drug: 50 mg/m2 aldoxorubicin
Drug: 100 mg/m2 aldoxorubicin

First Posted Date: 2014-01-07

Last Posted Date: 2024-06-11

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 15

Registration Number: NCT02029430

Locations: 🇺🇸
Louisiana State University Health Science Center, New Orleans, Louisiana, United States

Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma

Phase 2

Completed

Conditions: Glioblastoma

Interventions: Drug: 350 mg/m2 aldoxorubicin
Drug: 250 mg/m2 aldoxorubicin

First Posted Date: 2013-12-18

Last Posted Date: 2024-05-29

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 28

Registration Number: NCT02014844

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸
Ochsner Health System, New Orleans, Louisiana, United States

and more 1 locations

Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: aldoxorubicin

First Posted Date: 2012-10-15

Last Posted Date: 2022-02-10

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 18

Registration Number: NCT01706835

Locations: 🇺🇸
Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States

Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: aldoxorubicin

First Posted Date: 2012-08-28

Last Posted Date: 2022-02-10

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 15

Registration Number: NCT01673438

Locations: 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States

Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: INNO-206

First Posted Date: 2012-04-19

Last Posted Date: 2024-06-06

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 15

Registration Number: NCT01580397

Locations: 🇺🇸
Scottsdale Healthcare, Scottsdale, Arizona, United States
🇺🇸
Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States

and more 3 locations

Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Metastatic Soft Tissue Sarcoma
Locally Advanced Soft Tissue Sarcoma
Unresectable Soft Tissue Sarcoma

Interventions: Drug: INNO-206
Drug: Doxorubicin

First Posted Date: 2012-01-23

Last Posted Date: 2024-05-29

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 126

Registration Number: NCT01514188

Locations: 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States

and more 29 locations

Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Malignant Solid Tumour

Interventions: Drug: INNO-206

First Posted Date: 2011-04-19

Last Posted Date: 2022-02-10

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 24

Registration Number: NCT01337505

Locations: 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States

QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Biological: Neukoplast™ (NK-92)

First Posted Date: 2009-05-13

Last Posted Date: 2022-04-05

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 7

Registration Number: NCT00900809

Locations: 🇺🇸
UPMC Cancer Center - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy